Item 1.01. Entry into a Material Definitive Agreement
On
The Notes were sold pursuant to a pricing agreement, dated
Abbott may redeem some or all of the Notes of each series at any time at its option, in whole or from time to time in part, at the redemption prices specified in the applicable Note. Abbott intends to use the net proceeds from the Notes offering for general corporate purposes, which may include, without limitation, the repayment of indebtedness.
Please refer to the Prospectus Supplement, dated
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
The information included in Item 1.01 of this report is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description 1.1 Pricing Agreement 4.1 Indenture, dated as ofMarch 10, 2015 , betweenAbbott Laboratories andU.S. Bank National Association (including form of security) (previously filed as an exhibit to Abbott's Current Report on Form 8-K, filed with theSEC onMarch 10, 2015 ) Officers' Certificate Pursuant to Sections 3.1 and 3.3 of the Indenture with respect to 1.150% Notes due 2028 and 1.400% Notes due 4.2 2030 Form of 1.150% Notes due 2028 (included in Exhibit 4.2 of this 4.3 Current Report on Form 8-K) Form of 1.400% Notes due 2030 (included in Exhibit 4.2 of this 4.4 Current Report on Form 8-K) 5.1 Opinion ofWachtell, Lipton, Rosen & Katz Consent ofWachtell, Lipton, Rosen & Katz (included in Exhibit 5.1 23.1 of this Current Report on Form 8-K) Cover Page Interactive Data File (the cover page XBRL tags are 104 embedded in the Inline XBRL document) 2
© Edgar Online, source